Skip to content
Research Article Open access CC BY 4.0

Anti-HIV Drug Discovery, Development and Synthesis of Delavirdine: Review Article

Wollela Behja, Mudin Jemal

International Research Journal of Pure and Applied Chemistry · pp. 1–16 · Published 21 Dec 2019

10.9734/irjpac/2019/v20i330137

Abstract

Viruses are the smallest infectious agents of animal and plant tissues. Viruses are totally dependent on living cells to survive as they utilize the host cell's own replication processes, in order to reproduce themselves. HIV is the causative agent of AIDS. HIV is an unusually difficult to treat because it incorporate its own genetic material into the genome of an infected host cell. It infects T cells that carry the CD4 antigen on their surface. Binding and fusion, reverse transcription, integration, transcription, assembly and budding are the major steps of the HIV life cycle. The HIV/AIDS disease is treated by interrupting the HIV life cycle with specially designed drugs. The discovery of effective drugs against HIV has focused on targeting various critical components of the replication cycle of HIV. Depending on the target within the HIV replicative cycle they interact with, anti-HIV compounds are categorized into six groups. These are: nucleoside (nucleotide) reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), cell entry inhibitors or fusion inhibitors (FIs), co-receptor inhibitors (CRIs) and integrase inhibitors (INIs). The development of effective anti-HIV drugs is difficult due to wide variations in nucleotide and amino acid sequences. The development of anti-HIV drug passes through several important steps. This includes development from α-APA to ITU, ITU to DATA, DAPY to etravirine. Fosdevirine, lersivirine and rilpivirine are among the drugs that were undergoing clinical development and finally only rilpivirine was approved by FDA. The synthesis of delavirdine employs the use of heterocyclic rings like substituted pyridine and indole.

Human immunodeficiency virus HIV life cycle anti-HIV drugs and delavirdine

Cited by 11

Advancements in antiviral activity of aza-heterocyclic compounds: a review

Issam Ameziane El Hassani, Khalid Karrouchi, M’hammed Ansar · Molecular Diversity · 2025

In-vitro Study of HIV-derived Reverse Transcriptase Inhibition

Hussan Ibne Shoukani, Khudija tul Kubra, Bashir Ahmad · Anti-Infective Agents · 2025

Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches

Pedro N. Batalha, Luana S.M. Forezi, Carolina G.S. Lima · Bioorganic Chemistry · 2021

Zinc C293 as a novel scaffold with dual activity against HIV-1 integrase and reverse transcriptase

Sharif Karim Sayyed, Marzuqa Quraishi, Satish Kumar Rajasekharan · Computational Biology and Chemistry · 2025

Recent Advancements in Indole Derivatives and their Antimicrobial Perspective

Arvind Kumar, Deepika Kumari, Harpreet Singh · Letters in Organic Chemistry · 2023

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

11

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.